Femtech Startup Funding Statistics
Femtech startup funding statistics show 2024, 2025, and 2026 investment signals across women’s health, fertility, menopause, maternal health, diagnostics, and regional gaps.
TL;DR: Femtech startup funding statistics point to a sector with real momentum and messy measurement as of May 2026. SVB reported record women’s health VC investment of $2.6 billion in 2024, up 55% from 2023, and $10.7 billion when related conditions that affect women differently or disproportionately are included. Deloitte’s narrower health-tech analysis said women’s health investment fell 56% in 2025, from nearly $1.2 billion to $478 million, while overall health-tech funding rose to $28.6 billion. The World Economic Forum and BCG reported in January 2026 that women’s health captured only 6% of private healthcare investment, with 90% of that funding flowing into women’s cancers, reproductive health, and maternal health. The strongest current startup signals are menopause and midlife care, employer benefits, maternal risk management, fertility operations, diagnostics, pelvic health, privacy-safe data, and clinically credible care models.
Most Citeable Stats
Women’s health VC investment reached $2.6 billion in 2024, a 55% increase from 2023, according to SVB’s 2025 Innovation in Women’s Health report.
When SVB expanded the category to include health issues that affect women differently or disproportionately, US and European women’s health investment reached about $10.7 billion in 2024, according to SVB.
Deloitte’s PitchBook-based health-tech analysis found that women’s health investment fell 56% in 2025, from nearly $1.2 billion to $478 million, while overall health-tech venture funding rose nearly 30% to $28.6 billion, according to Deloitte.
Women’s health received only 6% of private healthcare investment despite women making up nearly half the world’s population, according to the World Economic Forum and BCG 2026 Women’s Health Investment Outlook.
Of the limited private capital going into women’s health, 90% flowed into women’s cancers, reproductive health, and maternal health, leaving menopause, osteoporosis, cardiovascular disease, Alzheimer’s, and other high-burden areas undercapitalized, according to BCG’s summary of the WEF report.
The women’s health gap costs 75 million years of life globally, and closing it could add at least $1 trillion to the global economy annually by 2040, according to the World Economic Forum.
AOA Dx’s 2026 exits analysis documented more than $100 billion in women’s health exit value across 276 exits and 27 billion-dollar transactions since 2000, according to AOA Dx.
Flo Health raised more than $200 million in July 2024 and crossed a $1 billion valuation, becoming the first purely digital consumer women’s health app to reach unicorn status, according to Flo Health.
Key Statistics
SVB said women’s health investment more than tripled between 2019 and 2024, outpacing broader healthcare investment growth, according to SVB.
SVB reported that healthtech’s share of women’s health VC investment fell from 54% in 2021 to 38% in 2024, while biopharma’s share rose from 12% to 34%, according to SVB’s 2025 report announcement.
In 2024, seed and Series A deals made up 70% of women’s health investment deals, close to the 67% share for overall healthcare, according to SVB.
Women’s health precision medicine investment reached $3.6 billion in 2024, up from $1.4 billion in 2023, according to SVB’s 2025 report announcement.
Forbes’ April 2026 coverage of SVB’s newer women’s health report said $1.58 billion was invested in women’s health in 2025, with two new unicorns already in Q1 2026, according to Forbes.
The World Economic Forum and BCG said less than 1% of private healthcare investment flows to companies focused exclusively on women’s health needs, according to BCG.
AOA Dx’s exits report found that diagnostics, biopharma, and devices accounted for nearly 80% of women’s health exit value, according to AOA Dx’s launch announcement.
AOA Dx said nearly half of all women’s health exits occurred in the past five years, showing that the exit base is more mature than old femtech labels suggest, according to AOA Dx.
Dealroom reported that North American femtech funding dropped nearly two-thirds from 2021 to 2023, while EMEA femtech funding fell about 50% over the same period, according to Dealroom’s femtech guide.
PitchBook reported in October 2024 that about $1.2 billion had been invested in femtech startups globally since the start of 2024, putting the category on track to challenge 2021’s $1.9 billion record, according to PitchBook.
Maven Clinic raised a $125 million Series F in October 2024, bringing total funding to more than $425 million, and Maven said the round valued the company at $1.7 billion, according to Maven Clinic.
Maven reported that more than 2,000 clients in 175 countries used its women’s and family health platform as of October 2024, according to Maven’s Series F announcement.
Midi Health raised a $100 million Series D in February 2026 at a valuation above $1 billion and said its insurance coverage reached more than 45 million women, according to Midi Health.
Pomelo Care raised $92 million in Series C funding in January 2026 at a $1.7 billion valuation and said it covered more than 25 million lives, according to Fierce Healthcare.
The Gates Foundation committed $2.5 billion through 2030 to accelerate women’s health R&D across more than 40 innovations in maternal, menstrual, gynecological, and sexual health, according to the Gates Foundation.
The CDC reported that the US maternal mortality rate was 17.9 deaths per 100,000 live births in 2024, with 649 maternal deaths, according to CDC NCHS.
The FTC finalized a 2021 order requiring Flo Health to get affirmative consent before sharing users’ personal health information after alleging the app shared sensitive data with marketing and analytics firms, according to the Federal Trade Commission.
Femtech Funding Snapshot
Funding Definitions Change the Story
Femtech Startup Models by Bootstrapper Fit
MeanCEO Index: Femtech Founder Opportunity
The MeanCEO Index scores practical femtech founder opportunity from 1 to 10 through an operator lens. The score weighs buyer urgency, capital efficiency, speed to first revenue, clinical trust, privacy risk, regulatory load, evidence quality, distribution difficulty, and whether a small team can prove value before raising a large round.
What The Numbers Mean For Bootstrapped Founders
Femtech bundles many separate problems that became visible because women kept paying for broken care with time, money, pain, and missed work.
That is good for founders who can build a paid workflow. It is bad for founders who think women’s health is a pink landing page, a community feed, and a few generic wellness tips.
The bootstrapped openings are practical:
- Help women understand and act on health data without selling panic.
- Help clinics reduce admin around intake, scheduling, follow-up, and reimbursement.
- Help employers offer women’s health benefits that people actually use.
- Help payers reduce avoidable ER visits, NICU days, complications, and missed follow-up.
- Help women in midlife connect menopause, metabolic health, sleep, mood, work, and strength.
- Help women’s health apps become privacy-safe enough to deserve sensitive data.
- Help underserved conditions move from vague symptoms to documented care pathways.
For adjacent healthcare context, compare this page with digital health startup statistics by region, health AI startup funding statistics, mental health startup statistics, longevity startup funding statistics, and GLP-1 startup statistics. Femtech overlaps with each of these when the product touches clinical workflow, behavior change, prevention, metabolic health, or care access.
Mean CEO Take
My founder read: femtech has finally reached the point where the lazy takes are becoming expensive.
The sector is too large to be dismissed as a niche, and too clinical to be treated as a lifestyle mood board. The smart money is moving where women’s health connects to outcomes: diagnostics, biopharma, care navigation, employer benefits, menopause, maternal risk, chronic disease, and privacy-safe data.
For bootstrappers, that is good news. You can build a real business without becoming the next Maven or Flo. You need one painful workflow, one buyer with budget, and one measurable improvement. A menopause clinic needs follow-up. A fertility clinic needs coordination. A payer needs maternal risk reduced. A women’s health app needs privacy controls. A founder in Europe needs a route through trust, evidence, and reimbursement without letting grants become the business.
Female founders should take this category seriously, but they should avoid being flattered into undercharging. Lived experience can reveal the pain. Pricing, compliance, clinical review, and distribution still decide whether the product becomes a company. Women’s health deserves ambitious companies and serious commercial language.
The biggest trap is building for applause inside the women’s health echo chamber. Build for the room where budget is approved.
Why Femtech Funding Numbers Disagree
The difference between $478 million, $1.58 billion, $2.6 billion, and $10.7 billion comes from taxonomy.
Deloitte’s 2026 analysis focused on health-tech investments. That lens is useful for software, virtual care, benefits, and app founders. It also leaves out much of the biopharma, diagnostics, and device activity that SVB and AOA Dx show is increasingly important.
SVB’s 2025 women’s health report used a broader healthcare lens and found a record $2.6 billion in 2024 women’s health investment. It also showed that biopharma became a much larger part of the category, rising from 12% of investment in 2021 to 34% in 2024. That shift explains why app-only femtech funding can look weaker while broader women’s health innovation looks stronger.
AOA Dx looked at exits. That lens exposes a different market again: diagnostics, oncology, biopharma, and devices were often never tagged as women’s health in venture databases, even when the product served women’s health needs.
The founder lesson is simple: define your category by buyer, evidence, and payment path before you use the fashionable label.
What Got Funded
The largest visible femtech and women’s health rounds show where investors believe scale can happen.
Flo Health proved that a consumer app can become a large subscription business when it combines daily utility, clinical review, lifecycle expansion, privacy positioning, and global scale. Its July 2024 Series C valued the company above $1 billion after more than eight years of growth.
Maven Clinic proved that employer and payer distribution can support a women’s and family health platform. Its October 2024 Series F brought total funding above $425 million and supported a broader platform across fertility, pregnancy, parenting, pediatrics, menopause, and value-based care.
Midi Health proved that menopause and midlife care can become a venture-scale category. Its February 2026 Series D crossed a $1 billion valuation and came with a clear care-platform story: insurance coverage, clinician network, AI-supported operations, and a shift from menopause into longitudinal women’s healthcare.
Pomelo Care proved that maternal health can be sold through outcomes and payer ROI. Its January 2026 Series C valued the company at $1.7 billion and positioned the platform beyond maternity into women’s and children’s health.
For bootstrapped founders, distribution matters more than the unicorn label:
- Flo owns consumer attention.
- Maven owns employer and global benefits distribution.
- Midi owns insurance-covered midlife care.
- Pomelo owns payer and maternal-risk economics.
Pick the distribution path before you write the pitch deck.
Where Capital Still Misses Women
The WEF and BCG finding that women’s health receives only 6% of private healthcare investment is the cleanest funding-gap statistic. The deeper issue is where the limited capital goes. If 90% of women’s health investment clusters around women’s cancers, reproductive health, and maternal health, then many high-burden categories remain thinly funded.
That matters because women’s health is broader than fertility and pregnancy.
The underfunded areas include:
- Menopause and perimenopause.
- Cardiovascular disease in women.
- Osteoporosis and musculoskeletal health.
- Alzheimer’s and brain health.
- Autoimmune conditions.
- Chronic pain and pelvic pain.
- Endometriosis and PCOS.
- Mental health across hormonal life stages.
- Metabolic health in midlife.
- Caregiving stress and workforce retention.
The World Economic Forum’s May 2026 women’s health data makes the business case clear: women spend 25% more of their lives in poor health or with disability than men, and closing the gap could add at least $1 trillion annually to the global economy by 2040.
For founders, the opportunity is to turn that macro gap into a paid workflow. A giant economic gap rarely pays invoices by itself.
Europe and Regional Gaps
Femtech’s regional picture is uneven.
The US remains the loudest market for large women’s health rounds because employer benefits, payer contracting, private insurance, venture capital, and consumer subscriptions can all support category leaders. Maven, Midi, Pomelo, and many fertility and maternal-health platforms fit that pattern.
Europe has a different shape. Dealroom’s femtech guide shows that EMEA held up slightly better than North America during the 2021 to 2023 pullback, but funding still fell by about 50%. Flo’s UK-based unicorn round is a strong signal, while most European femtech startups still face a hard funding path.
European founders can compete through:
- Trust and privacy.
- Medical evidence.
- Multilingual care.
- Public and private reimbursement discipline.
- Employer health benefits.
- Clinical partnerships.
- More conservative claims.
- Care for underserved midlife and chronic conditions.
The European trap is waiting for institutions to bless the company before customers buy. Grants, hospital pilots, accelerators, and public innovation programs can help, but the founder still needs a buyer with budget and urgency.
For low- and middle-income markets, the Gates Foundation’s $2.5 billion commitment matters because commercial VC alone is too limited to fund every maternal, menstrual, gynecological, contraceptive, and sexual health gap. Founders in these markets should watch non-dilutive funding, global health partnerships, public procurement, and distribution through clinics, pharmacies, NGOs, and insurers.
Privacy Is a Funding Issue
Femtech cannot treat privacy as a legal page pasted into the footer.
Cycle tracking, fertility, pregnancy, abortion-related data, menopause symptoms, sexual health, mental health, and hormone data are sensitive. Privacy failures can destroy trust faster than a bad onboarding flow.
The FTC’s Flo Health order is a reminder that women’s health apps handle data that users may believe is private even when analytics, advertising, and third-party tools are quietly involved. The business risk is bigger after the fall of Roe v. Wade in the US because reproductive data can feel legally and personally dangerous.
For founders, privacy can become a product wedge:
- Consent receipts.
- Data minimization.
- Anonymous mode.
- Vendor-risk reviews.
- Audit logs.
- No ad-tech tracking on sensitive flows.
- Clear deletion controls.
- Separate medical and marketing data.
- Human-readable privacy explanations.
The best femtech products will make privacy part of the value proposition and treat compliance as product quality.
Startup Ideas With Clear Revenue Paths
If I were testing a femtech startup without a giant round, I would start with one of these:
- A menopause care follow-up workflow for clinics, including symptoms, medication, sleep, metabolic health, and labs.
- A maternal-risk navigation service for one payer, employer, or Medicaid-adjacent population.
- A privacy and consent layer for women’s health apps that need to remove ad-tech risk.
- A fertility clinic operations tool for scheduling, benefits verification, patient education, or lab follow-up.
- A pelvic health triage and adherence program sold through physiotherapists, OB-GYNs, or employers.
- A women’s health benefits navigator for small and mid-sized companies.
- A menopause and metabolic health program for women founders and high-stress operators.
- A postpartum mental health follow-up workflow for clinics and doulas.
- A clinician-reviewed content and decision tool for one underdiagnosed condition.
- A grant-funded research-to-product bridge for gynecological and menstrual health in underserved markets.
The common pattern is paid proof. The product should save time, reduce cost, improve access, increase adherence, reduce risk, or help a buyer document outcomes.
Methodology
This article uses public and near-primary sources published through May 6, 2026. The source mix includes SVB women’s health reports and announcements, Deloitte’s PitchBook-based health-tech analysis, World Economic Forum and BCG women’s health investment reporting, AOA Dx exits data, company funding announcements, healthcare trade coverage, CDC maternal mortality data, FTC enforcement records, Dealroom and PitchBook market summaries, and the Gates Foundation’s women’s health R&D commitment.
The main caveat is category definition. "Femtech," "women’s health," "women’s health healthtech," and "expanded women’s health" need separate definitions. Some datasets count consumer apps and virtual care. Others include diagnostics, devices, oncology, biopharma, and conditions that affect women differently or disproportionately. Where figures conflict, this article labels the dataset and uses the narrowest defensible interpretation.
Funding figures represent disclosed or reported venture and private investment signals. Many private rounds, undisclosed valuations, secondary transactions, grants, and public-sector commitments are missing from venture datasets. Exit figures are also affected by disclosure gaps and historical category tagging.
Definitions
Products and services designed around women’s health needs, often including fertility, menstrual health, pregnancy, menopause, pelvic health, sexual health, and women-focused digital care.
A broader category that includes female-specific conditions, reproductive and maternal health, menopause, women’s cancers, and conditions that affect women differently or disproportionately.
A dataset approach that includes conditions such as cardiovascular disease, autoimmune disease, Alzheimer’s, osteoporosis, mental health, and oncology when female biology, burden, symptoms, diagnosis, or outcomes differ materially.
Women’s health companies focused on software, virtual care, apps, benefits, navigation, or digital healthcare delivery, usually excluding biopharma, diagnostics, and medical devices.
Equity capital invested in private companies, often across pre-seed, seed, Series A, growth, and late-stage rounds.
The disclosed value of acquisitions, mergers, IPOs, and other liquidity events. Exit datasets can undercount categories when companies were historically tagged under diagnostics, devices, oncology, or healthcare services instead of women’s health.
A practical score for whether a small founder team can test demand, reach first revenue, and prove value without heavy clinical trials, expensive hardware, or large regulated operations from day one.
FAQ
How much funding did femtech startups raise in 2024?
It depends on the definition. SVB reported $2.6 billion in 2024 women’s health VC investment and $10.7 billion when related conditions that affect women differently or disproportionately are included. PitchBook reported about $1.2 billion in femtech investment by October 2024 in a narrower women’s health startup dataset.
Why do femtech funding numbers vary so much?
Femtech datasets use different category boundaries. Some count only pure-play apps and women-specific digital care. Others include biopharma, devices, diagnostics, women’s cancers, autoimmune disease, cardiology, and conditions where women have different disease burden or outcomes.
Is femtech still underfunded?
Yes. The World Economic Forum and BCG reported in January 2026 that women’s health receives only 6% of private healthcare investment, and 90% of that funding flows into women’s cancers, reproductive health, and maternal health. Many high-burden areas remain undercapitalized.
Which femtech areas are most attractive for bootstrapped founders?
The best bootstrapped wedges are menopause care operations, maternal follow-up, employer benefits navigation, privacy and consent infrastructure, fertility clinic operations, pelvic health adherence, postpartum mental health workflows, and condition-specific care navigation. These can start with workflow proof before expensive clinical scale.
Are femtech startups producing exits?
Yes. AOA Dx’s 2026 Follow the Exits report documented more than $100 billion in women’s health exit value across 276 exits and 27 billion-dollar transactions since 2000. The issue is measurement: many exits were historically tagged under diagnostics, biopharma, devices, or oncology.
What is the biggest mistake femtech founders make?
The biggest mistake is treating women’s health as a branding category instead of a healthcare business. The buyer still needs proof, privacy, compliance, clinical credibility, and a reason to pay. Community and empathy help, but revenue comes from solving a specific workflow or outcome problem.
Violetta Bonenkamp, also known as Mean CEO, is a female entrepreneur and an experienced startup founder, bootstrapping her startups. She has an impressive educational background including an MBA and four other higher education degrees. She has over 20 years of work experience across multiple countries, including 10 years as a solopreneur and serial entrepreneur. Throughout her startup experience she has applied for multiple startup grants at the EU level, in the Netherlands and Malta, and her startups received quite a few of those. She’s been living, studying and working in many countries around the globe and her extensive multicultural experience has influenced her immensely. Constantly learning new things, like AI, SEO, zero code, code, etc. and scaling her businesses through smart systems.